普乐可复在肾移植中的临床应用探讨  

Clinical Application of FK506 in Renal Transplantation

作　　者：陈恺杰[1] 唐群业[2] 

机构地区：[1]广东医学院附属医院,广东湛江524001 [2]上海复旦大学附属中山医院,上海200032

出　　处：《河北医学》2005年第7期626-628,共3页Hebei Medicine

摘　　要：目的:评价普乐可复(FK506)对肾移植患者免疫抑制作用的疗效和安全性。方法:将70例肾移植患者分为两组。普乐可复组(n=35):主要用药为普乐可复+硫唑嘌呤(Aza)+泼尼松(Pred);环孢素A(CsA)组(n=35):主要用药为CsA+Aza+Pred。结果:观察6个月,普乐可复组急性排斥发生率为0,而CsA组有9例(25.7%)发生急性排斥反应(P<0.05);普乐可复组的肝毒性和神经毒性反应发生率均比CsA组低(P<0.05);普乐可复组有3例(8.6%)发生高血糖反应(P>0.05)。结论:普乐可复在肾移植中排斥发生率低,毒副作用小,是一种安全高效的新型免疫抑制剂。Objective: To investigate the immunosuppressive efficacy and safety of FK506 on renal transplant recipients. Method: 70 cases of renal transplant recipients were divided into two groups: FK506 group was treated with FK506+Aza+Pred, CsA group was treated with CsA+Aza+Pred. Result: After six months' observation, there is no acute rejection in FK506 group while 9 patients in CsA group(25.7%) presented acute rejection(P<0.05). Incidence of hepatotoxicity and neurotoxicity in FK506 group was lower than that of CsA group(P<0.05). 3 cases in FK506 group presented high blood glucose (8.6%)(P>0.05). Conclusion: FK506 is a new effective and safe immunity inhibitor in kidney transplant.

关 键 词：普乐可复 环孢素A 肾移植 

分 类 号：R699[医药卫生—泌尿科学]